SCARA3 is a scavenger receptor class A member that functions as a protective molecule against oxidative stress and harmful oxidation products. It is expressed across various tissues including adipose tissue and immune cells, with activity mediated through protein-binding interactions and endoplasmic reticulum localization 1. SCARA3 exhibits pleiotropic disease relevance: in cancer, reduced expression correlates with poor prognosis in lung cancer, multiple myeloma, and ovarian carcinoma, while SCARA3 overexpression inhibits proliferation and epithelial-mesenchymal transition through AKT signaling pathway suppression 23. In metabolic disorders, SCARA3 expression is reduced in obesity-related conditions and type 2 diabetes, with epigenetic hypermethylation observed in diabetic and atherosclerotic patients 4. SCARA3 protects myeloma cells against oxidative stress-induced killing, making it a biomarker for therapy resistance and disease progression 3. Additionally, SCARA3 associates with inflammatory and metabolic disease pathways, including rheumatoid arthritis and osteoarthritis as an RNA modification-related biomarker 5, and shows altered expression in response to environmental pollutant exposure 6. Clinically, SCARA3 induction sensitizes cancers to chemotherapy and represents a therapeutic target for improving treatment efficacy.